US says 'no concerns' with vaccines eyed in Japan deaths

Mar 07, 2011

US health officials said Monday they have had no reports that arouse new safety concerns over two children's vaccines that have been suspended in Japan following the deaths of four babies.

Researchers at the (FDA) and (CDC) "have not detected new safety concerns or unusual reporting patterns" among children given the vaccines against bacteria that can cause meningitis and pneumonia, FDA spokeswoman Shelly Burgess said.

Japanese health authorities ordered doctors to stop using the two vaccines -- Prevenar, made by US-based Pfizer, and ActHIB, made by the Sanofi Pasteur wing of Paris-headquartered Sanofi-Aventis -- following the deaths of four infants who were given the shots alone or in combination with others drugs.

The infants, aged from around six months to under two years old, all died between March 2 and 4, Japanese officials said.

In addition to the four cases, Japan's health ministry said another infant died in November after receiving his second shot of the ActHIB , a Japanese health ministry official said.

The FDA and CDC are aware of the babies' deaths and of the suspension of the two vaccines in , a statement sent by Burgess to AFP said.

US health agencies were continuing to monitor the safety of all vaccines, including those against the haemophilus influenzae type b (Hib) bacteria and streptococcus pneumoniae targeted by ActHIB and Prevenar, the statement said.

Explore further: FDA warns of compounded drug recall by Texas firm

add to favorites email to friend print save as pdf

Related Stories

Kids' Swine flu shots recalled; not strong enough

Dec 15, 2009

(AP) -- Hundreds of thousands of swine flu shots for children have been recalled because tests indicate the vaccine doses lost some strength, government health officials said Tuesday.

WHO: nearly 5,000 swine flu deaths worldwide

Oct 23, 2009

(AP) -- Nearly 5,000 people have reportedly died from swine flu since it emerged this year and developed into a global epidemic, the World Health Organization said Friday.

Recommended for you

EU regulator: Morning-after pill OK for all women

15 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

19 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

20 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

Jul 23, 2014

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Caliban
not rated yet Mar 07, 2011
What is the sample size? Are 5 fatalities of any statistical relevance? Why the sketchy info -almost zero context.